Evaluation and Management of Postsurgical Patient With Hirschsprung Disease Neurogastroenterology & Motility Committee: Position Paper of North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN)

Hirschsprung disease fundamentally involves the absence of ganglion cells in a section of bowel, preventing that section from relaxing properly during peristalsis and causing functional blockage.

The two major long-term issues affecting quality of life after Hirschsprung disease surgery are fecal incontinence and ongoing obstructive symptoms including persistent constipation and Hirschsprung-associated enterocolitis (HAEC).

Hirschsprung-associated enterocolitis (HAEC) occurs in 25% to 37% of patients after surgery and carries a mortality risk of up to 10%.

Post-operative constipation rates in Hirschsprung disease patients range from 6% to 40% in the literature.

Fecal incontinence rates in post-surgical Hirschsprung disease patients range from 8% to 74% in the literature.

Studies show Hirschsprung disease patients score lower in psychosocial quality of life compared to healthy children.

Effective management of post-surgical Hirschsprung disease requires a multidisciplinary team including colorectal surgeon, neurogastroenterologist, dietitian, specialized nurses, social worker, and psychologist, following the patient into adulthood.

Before functional testing in symptomatic post-surgical Hirschsprung patients, anatomical blockages and issues with the original surgery must be ruled out through detailed history, physical exam, growth assessment, pathology review, imaging, and examination under anesthesia.

Original pathology slides from Hirschsprung surgery must be reviewed by an experienced pathologist to confirm there is no residual aganglionosis, transition zone pull-through, or skip areas; if slides are unavailable or unclear, rebiopsy is necessary.

Mechanical obstructions after Hirschsprung surgery include anastomotic stricture (scar tissue narrowing the connection), kinking or twisting of pulled-through colon, tight muscle cuff in Soave procedures, residual spur in Duhamel procedures, or enlarged floppy pouch collecting stool.

Anorectal manometry (ARM) measures pressures and reflexes in the rectum and anal canal, assessing both voluntary control and involuntary functions.

In Hirschsprung disease patients, the internal anal sphincter often does not relax properly when the rectum fills with stool, resulting in absent recto-anal inhibitory reflex, which anorectal manometry can confirm by measuring sphincter pressures.

Colonic manometry is reserved for patients with persistent, refractory symptoms after other diagnostic steps and initial therapies, and provides a map of colonic contractility patterns including coordination, strength, and transit speed.

First-line treatment for functional obstruction in post-surgical Hirschsprung disease is daily stimulant laxatives (senosides or bisacodyl) dosed to achieve effective colonic emptying and decompression, which reduces HAEC risk.

When anorectal manometry confirms high pressures in a hypertonic, non-relaxing internal anal sphincter, botulinum toxin injection directly into the sphincter muscle is the targeted treatment.

Botulinum toxin injection is effective for obstructive symptoms in approximately 66% of Hirschsprung disease patients with hypertonic internal anal sphincter.

Botulinum toxin effect on the internal anal sphincter is temporary, typically lasting around 6 months, requiring repeat injections, but is preferred over permanent surgical myectomy because myectomy carries real risk of causing permanent fecal incontinence.

The critical first distinction in fecal incontinence management is determining whether it is retentive (overflow from severe constipation) or non-retentive (true sphincter or sensory dysfunction).

Retentive fecal incontinence is overflow incontinence where the patient is severely constipated and impacted, with liquid stool leaking around the blockage; the underlying problem is obstruction.

Non-retentive fecal incontinence is true incontinence where the colon is relatively empty but the patient cannot hold stool back effectively due to sphincter mechanism or sensation problems.

A radio-opaque marker study showing 5 or more markers remaining inside after 5 days points strongly towards significant retention, indicating retentive fecal incontinence.

The dentate line deep in the anal canal is packed with sensory nerves that help discriminate between gas, liquid, or solid stool; if damaged or removed during pull-through surgery, patients lose this discriminatory ability leading to accidents.

Initial conservative management for non-retentive fecal incontinence includes dietary changes (constipating diet), adding soluble fiber (pectin or psyllium) to absorb water and add bulk without loosening stool, and avoiding insoluble fiber which can worsen leakage.

Timed toilet sitting after meals is recommended to harness the gastrocolonic reflex in a controlled way for managing non-retentive fecal incontinence.

Anti-motility agents (loperamide, cholestyramine, hyoscyamine) are used to slow colonic transit and can help increase internal anal sphincter tone slightly in non-retentive fecal incontinence.

In some non-retentive fecal incontinence patients, colonic manometry reveals dramatic colonic hyperactivity with powerful rapidly moving high amplitude propagating contractions (HAPCs) that blast stool through the pulled-through bowel and out the anus.

The sigmoid colon normally acts as a storage area and brake, but is often removed or altered in pull-through surgery, eliminating the stopping point for colonic contractions.

When colonic manometry confirms hyperactive colon with runaway contractions as the mechanism of non-retentive fecal incontinence, laxatives are contraindicated and targeted anti-motility agents to reduce HAPCs and slow the colon are the correct treatment.

If non-retentive fecal incontinence persists despite optimized medical therapy, the next steps are structured emptying programs starting with low-volume retrograde enemas, then considering antegrade continence enemas (ACE).

In an ACE procedure, the surgeon creates a small channel (usually connecting the appendix or tube to the abdominal skin) allowing the patient or caregiver to administer enema fluid directly into the beginning of the colon each day, flushing everything out from above in a predictable way.

Antegrade continence enemas (ACE) have success rates of 69% to 91% for improving continence and quality of life in refractory fecal incontinence.

ACE is seen as the critical step before contemplating major resections or creating a permanent stoma (ostomy bag) for refractory fecal incontinence.